²é¿´: 1749  |  »Ø¸´: 9
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

Ãγ¾ÒÝ

гæ (³õÈëÎÄ̳)

[ÇóÖú] ÇóÖú£¬ÕâÑù˵ÎÄÕÂÄܲ»Äܱ»½ÓÊÜ£¿

±¾ÈËǰһ¶Îʱ¼äÔÚinternational immunopharmacologyÉÏÍ·ÁËһƪÎÄÕ£¬Ó°ÏìÒò×Ó²»¸ß2.3°É£¬Éó¸åÒâ¼û»ØÀ´ÁË£¬ÓÐÒ»¸öÉó¸åÈ˾ÍÌáÁË3¸öÎÊÌ⣬»¹¶¼ÊÇСÎÊÌ⣬»ù±¾Ã»Ê²Ã´Ê£¬²»¹ýÁíÒ»¸öÉó¸åÈËÈ´ÊÇÕâô˵µÄ
Reviewer #2: The authors of this study claimed that synergistic effects of blocking IL-1beta and IL-17A could suppress the rheumatoid development in CIA mouse model.  Blocking of IL-1 and IL-17signaling pathway have been shown playing function in delaying or preventing the development of rheumatoid arthritis. In this study, the authors did not point out any new information in addition to well-documented. Detailed mechanism on how those two molecules play a synergistic effect is more favored.
And there are also several other questions.
1. The whole experiment was done in DBA mice, why humanized antibodies were used? Please justify the structural similarity of both human and murine IL-1 beta and IL-17A as well as the crossreactivities of those blocking antibody.
2. In 3.4 and 3.5, as author stated, it should be ex vivo experiment but not in vitro.

ÇóÖú´óÉñÃÇÕâÖÖÒâ¼ûÓ¦¸ÃÔõô°ìÄØ£¬ÎÊÌâÑϲ»ÑÏÖØ°¡£¿ÎÒ×îºÃÔõô»Ø´ðËû£¬ÒѾ­À§ÈźþÃÁË
»Ø¸´´ËÂ¥

» ÊÕ¼±¾ÌûµÄÌÔÌûר¼­ÍƼö

decision in progress

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

nono2009

³¬¼¶°æÖ÷ (ÎÄѧ̩¶·)

No gains, no pains.

ÓÅÐãÇø³¤ÓÅÐãÇø³¤ÓÅÐãÇø³¤ÓÅÐãÇø³¤ÓÅÐã°æÖ÷

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
±à¼­ÈÃÄã¸Ä£¬ËµÃ÷Ï£ÍûºÜ´ó¡£ºÃºÃ¸Ä£¬²»ÄܸÄÒ²ºÃºÃ½âÊÍ
3Â¥2012-11-19 19:42:59
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 10 ¸ö»Ø´ð

Ãγ¾ÒÝ

гæ (³õÈëÎÄ̳)

×Ô¼º¶¥Ï£¬¹òÇóÒâ¼û
2Â¥2012-11-19 16:29:25
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xianjin1985

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
¸Ð¾õÓ¦¸Ã»áÓлú»á±»½ÓÊÜ£¬Ö»ÒªÈÏÕæÈ¥¸Ä£¬²¢ÇÒ¶ÔµÚ¶þ¸öÉó¸åÈ˵ÄÒâ¼ûÊʵ±½ÓÊÜ£¬¿´×Ô¼ºÔõô¸ÄÁ˰É
4Â¥2012-11-19 20:15:38
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

visitor958

ÖÁ×ðľ³æ (ÎÄ̳¾«Ó¢)

IEEEÔÓÖ¾Óë»áÒéר¼Ò

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
Õâ¸öÒ»¶¨ÒªÈÏÕæ¿ÍÆøµÄ»Ø¸´£¬Ä㾡Á¿°É£¬Éó¸åÈËÓеļá³Ö£¬ÓеĿ´µ½±à¼­Ã»Óоܣ¬¾ÍËãÁË£¨¾¡Á¿²»Õұ༭Âé·³£©¡£¡£¡£
5Â¥2012-11-19 20:43:28
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Ò»Ö¾Ô¸985£¬±¾¿Æ211£¬0817»¯Ñ§¹¤³ÌÓë¼¼Êõ319Çóµ÷¼Á +10 Liwangman 2026-03-15 10/500 2026-03-19 10:25 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] ²ÄÁÏר˶ӢһÊý¶þ306 +5 z1z2z3879 2026-03-18 5/250 2026-03-19 07:43 by BruceLiu320
[¿¼ÑÐ] ²ÄÁϹ¤³Ìר˶µ÷¼Á +5 204818@lcx 2026-03-17 6/300 2026-03-18 22:55 by 204818@lcx
[¿¼ÑÐ] 311Çóµ÷¼Á +4 ¶¬Ê®Èý 2026-03-18 4/200 2026-03-18 21:47 by ¾¡Ë´Ò¢1
[¿¼ÑÐ] 328Çóµ÷¼Á£¬Ó¢ÓïÁù¼¶551£¬ÓпÆÑо­Àú +3 ÉúÎ﹤³Ìµ÷¼Á 2026-03-17 7/350 2026-03-18 20:41 by Wangjingyue
[¿¼ÑÐ] Ò»Ö¾Ô¸Ìì½ò´óѧ»¯Ñ§¹¤ÒÕרҵ£¨081702£©315·ÖÇóµ÷¼Á +10 yangfz 2026-03-17 10/500 2026-03-18 20:14 by walc
[¿¼ÑÐ] 331Çóµ÷¼Á£¨0703Óлú»¯Ñ§ +7 ZY-05 2026-03-13 8/400 2026-03-18 14:13 by 007_lilei
[¿¼ÑÐ] 312Çóµ÷¼Á +8 İå·Ï£ 2026-03-16 9/450 2026-03-18 12:39 by Linda Hu
[¿¼ÑÐ] 280Çóµ÷¼Á +6 ¹¾ààÏþÏþ 2026-03-18 7/350 2026-03-18 11:25 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] 265Çóµ÷¼Á +3 ÁºÁºÐ£Ð£ 2026-03-17 3/150 2026-03-18 09:12 by zhukairuo
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼ÑÐ] ÓÐûÓеÀÌú/ÍÁľµÄÏëµ÷¼ÁÄÏÁÖ£¬¸ø×Ô¼ºÕÐʦµÜÖС« +3 TqlXswl 2026-03-16 7/350 2026-03-17 15:23 by TqlXswl
[ÂÛÎÄͶ¸å] ÓÐûÓдóÀз¢Ð¡ÂÛÎÄÄÜ´øÎÒ¸ö¶þ×÷ +3 ÔöÈñ©ÈË 2026-03-17 4/200 2026-03-17 09:26 by xs74101122
[¿¼ÑÐ] 11408 Ò»Ö¾Ô¸Î÷µç£¬277·ÖÇóµ÷¼Á +3 zhouzhen654 2026-03-16 3/150 2026-03-17 07:03 by laoshidan
[»ù½ðÉêÇë] ½ñÄêµÄ¹ú»ù½ðÊÇ´ò·ÖÖÆÂ𣿠50+3 zhanghaozhu 2026-03-14 3/150 2026-03-16 17:07 by ±±¾©À³ÒðÈóÉ«
[¿¼ÑÐ] 304Çóµ÷¼Á +3 ÂüÊâ2266 2026-03-14 3/150 2026-03-16 16:39 by houyaoxu
[¿¼ÑÐ] 070305Çóµ÷¼Á +3 mlpqaz03 2026-03-14 4/200 2026-03-15 11:04 by peike
[¿¼ÑÐ] ±¾¿ÆÄϾ©´óѧһ־Ը´¨´óҩѧ327 +3 ÂóÌï¸ûÕß 2026-03-14 3/150 2026-03-14 20:04 by ÍâÐÇÎÄÃ÷
[¿¼ÑÐ] 255Çóµ÷¼Á +3 Àî¼Î»Û£¬ 2026-03-12 4/200 2026-03-14 16:58 by ÓÐÖ»ÀêÅ«
[¿¼ÑÐ] 266Çóµ÷¼Á +4 ѧԱ97LZgn 2026-03-13 4/200 2026-03-14 08:37 by zhukairuo
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û